Non Metastatic clinical trials

JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer

This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.

Probiotic supplement for advanced lung cancer

This trial tests if taking a probiotic supplement along with your standard lung cancer treatment can help you live longer and respond better to therapy. It is for people with advanced non-small cell lung cancer who have not tried immunotherapy before.

Imzokitug plus pumitamig and chemo for first-line advanced lung cancer

This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.

Combination targeted therapy for KRAS G12C lung cancer

This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Morning vs. afternoon immunotherapy for advanced solid tumors

This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.

Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer

This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.

Combination therapy for STK11-mutant lung cancer

This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.

Study of a new antibody for advanced tumors with FGFR1 protein

This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.

Study of SHR-A2102 and Adebrelimab for advanced lung cancer

This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.

Study of SHR-8068 with adebrelimab and chemo for lung cancer

This trial tests a new combination of drugs (SHR-8068 plus adebrelimab and chemotherapy) against another approved combination for people with advanced non-small cell lung cancer who have not had treatment yet. The goal is to see which combination works better.

SBRT radiation plus standard treatment for spread cancer

This trial looks at adding a focused radiation treatment called SBRT to standard care for cancers that have spread to a limited number of spots. It aims to control those spread-out tumors while still using the usual cancer treatment plan.

Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer

This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.

Darolutamide Plus Hormone Therapy for Prostate Cancer in China

This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.

Safety and early results of AST2303 for advanced lung cancer

This trial tests a new oral drug, AST2303 (ABK3376), in people with advanced non-small cell lung cancer that has not responded to other treatments. It aims to see if the drug is safe and whether it can shrink tumors.

Maintenance cabozantinib plus pembrolizumab after lung cancer control

This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.

Standard vs longer radiation for brain metastases

This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.

Trial: Adjusting Atezolizumab Dose Based on Drug Levels in Blood

This study tests whether adjusting the dose of the immunotherapy drug atezolizumab (Tecentriq) based on its levels in your blood works well. You may be able to join if you have advanced cancer and your doctor already plans to give you this drug (alone or with other approved treatments).

Study of nivolumab with chemo before lung cancer surgery

This study looks at how well the immunotherapy drug nivolumab (Opdivo) works when given with standard chemotherapy before surgery for people with a certain type of lung cancer that has not spread. It may help shrink the tumor before surgery.

Comparing a new drug combo for advanced lung cancer with a specific gene change

This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.

PET Scan to Track Lung Cancer Treatment Response

This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.

Sparing memory during brain radiation for leptomeningeal metastases

This trial tests a special type of radiation that avoids the memory center of the brain (the hippocampus) while treating cancer that has spread to the lining of the brain and spinal cord. It may help reduce side effects on thinking and memory for people with breast or lung cancer.

Radiation for cancer spread to brain lining

This trial tests whether a precise type of radiation to the brain and spine (craniospinal irradiation) can help control cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease) in people with breast cancer or non-small cell lung cancer. The goal is to improve symptoms and slow disease progression.

A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer

This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.